TheBrief.Health

What the FDA Approval and Phase 3 Data for Enlicitide Means for Preventive Cardiology

Episode Summary

FDA-approved oral PCSK9 inhibitor enlicitide offers once-daily LDL-C lowering, potentially expanding treatment options for high-risk patients unable or unwilling to use injectable therapies.